Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, In… Read more
Galecto Inc (GLTO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.392x
Based on the latest financial reports, Galecto Inc (GLTO) has a cash flow conversion efficiency ratio of -0.392x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.62 Million) by net assets ($6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galecto Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Galecto Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Galecto Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galecto Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
biote Corp
NASDAQ:BTMD
|
-0.215x |
|
Westport Fuel Systems Inc
NASDAQ:WPRT
|
0.007x |
|
Western Carriers India Ltd
NSE:WCIL
|
N/A |
|
West Point Gold Corp.
OTCQB:WPGCF
|
-0.102x |
|
Pacific West Bancorp
PINK:PWBK
|
0.028x |
|
Starbreeze AB (publ)
PINK:STBEF
|
0.077x |
|
Arcario AB
ST:ARCA
|
-0.083x |
|
Chungdamglobal Co. Ltd.
KQ:362320
|
-0.095x |
Annual Cash Flow Conversion Efficiency for Galecto Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Galecto Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $15.83 Million | $-18.62 Million | -1.176x | -3.04% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |